Literature DB >> 6193457

Activated T lymphocytes in patients with multiple sclerosis.

J Golaz, A Steck, L Moretta.   

Abstract

We used four monoclonal antibodies designated MLR-1, -2, -3, and -4, specifically directed against determinants uniquely present on activated T lymphocytes to analyze peripheral blood lymphocytes (PBL) of patients with multiple sclerosis (MS). By indirect immunofluorescence techniques, we found that many PBL expressed one or more of these activation antigens. Thus, high percentages of MLR-2 positive cells were found in all 20 MS patients (66 +/- 12% in 13 patients with the remitting form and 57 +/- 14% in 7 patients with the progressive form). MLR-3 positive cells were found in three patients with the remitting form and five patients with progressive MS, MLR-4 in seven patients with remitting MS and in five with the progressive type. MLR-1 positive cells were prominent in only two cases (one remitting and one progressive). Discrepancies between expression of MLR antigens and molecules coded by the HLA-DR region (Ia antigens) were observed.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6193457     DOI: 10.1212/wnl.33.10.1371

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  8 in total

1.  Dual labelling of circulating CD8 cells in patients with multiple sclerosis.

Authors:  P J Hughes; P F Kirk; D A Compston
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-01       Impact factor: 10.154

2.  Cathepsin D activity in human peripheral blood mononuclear leukocytes.

Authors:  C T Bever; K D Morgan; J N Whitaker
Journal:  Inflammation       Date:  1989-06       Impact factor: 4.092

3.  Determination of activated lymphocytes in peripheral blood of patients with multiple sclerosis.

Authors:  A D Crockard; T A McNeill; J McKirgan; S A Hawkins
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-01       Impact factor: 10.154

4.  HLA-DR antigen expression on T cells from cerebrospinal fluid in multiple sclerosis and aseptic meningo-encephalitis.

Authors:  S Fredrikson; A Karlsson-Parra; T Olsson; H Link
Journal:  Clin Exp Immunol       Date:  1987-05       Impact factor: 4.330

5.  Local and systemic immune response in multiple sclerosis: analysis of CSF inflammatory changes and peripheral blood T-cell subsets.

Authors:  A J Steck; J C de Flaugergues
Journal:  J Neurol       Date:  1984       Impact factor: 4.849

6.  Tumour necrosis factor alpha is elevated in serum and cerebrospinal fluid in multiple sclerosis and inflammatory neuropathies.

Authors:  M Rentzos; C Nikolaou; A Rombos; K Voumvourakis; I Segditsa; C Papageorgiou
Journal:  J Neurol       Date:  1996-02       Impact factor: 4.849

7.  Intravenous gammaglobulin treatment in multiple sclerosis and experimental autoimmune encephalomyelitis: delineation of usage and mode of action.

Authors:  A Achiron; R Gilad; R Margalit; U Gabbay; I Sarova-Pinhas; I R Cohen; E Melamed; O Lider; S Noy; I Ziv
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-11       Impact factor: 10.154

8.  Multiple sclerosis: effect of myelin basic protein on interleukin 1, interleukin 2 production and interleukin 2 receptor expression in vitro.

Authors:  K Selmaj; Z Nowak; H Tchórzewski
Journal:  Clin Exp Immunol       Date:  1988-06       Impact factor: 4.330

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.